Sign In
Section Navigation
Common TitleMK-1439-007
Official Title Multicenter, Double-Blind, Randomized, 2-Part, Dose Ranging Study to Compare the Safety, and Antiretroviral Activity of Doravirine (MK-1439) Plus TRUVADA Versus Efavirenz Plus TRUVADA in Antiretroviral Treatment-Naive, HIV-1 Infected Patients
Phase Phase IIB
ClinicalTrials.gov NCT01632345
Treatments
Doravirine
Doravirine Pifeltro

Doravirine

Tradename:PifeltroOther Names:DORClass:Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTI)
Categories Treatment-Naive
Funding
IndustryMerck Sharp & Dohme Corp
References
  • Gatell JM, Morales-Ramirez JO, Hagins DP, et al. Doravirine dose selection and 96-week safety and efficacy versus efavirenz in antiretroviral therapy-naive adults with HIV-1 infection in a Phase IIb trial. Antivir Ther. 2019;24:425-35.
    [PubMed Abstract]

Share by e-mail

Since you've received 80% or better on this quiz, you may claim continuing education credit.

You seem to have a popup blocker enabled. If you want to skip this dialog please Always allow popup windows for the online course.